 Steve, it's good to have you here and you've been very busy. You've had a lot of news the last little while and I just want to briefly touch on some of them. Let's start with your spectacular quarter results. You showed record revenues again. That's correct. That's a third consecutive quarter of revenue growth and we foresee that projecting out for the next 12 to 16 quarters. Some runway ahead of us, but we did record revenues of $6.1 million in Q3, which ended July 31. That was up 27% over Q2. Our gross margins were 34% higher in Q2 and as importantly, our adjusted EBITDA loss was about a million dollars less than Q2. Revenues, margins are going up. Our loss is going down and those are trends that we expect to see continue over the quarters to come. And the other question everyone always asks, you have $27 million in the bank. That's correct. So we closed the financing just before quarter end of $30 million U.S. which was used to fund the acquisition of three additional products which are creative immediately to us. The three products had the existing revenues of $27 million and we expect that to grow. So our total revenue base basically doubled on the day that we made that acquisition and that funding should allow us to get to breakeven and beyond save for any other acquisitions that we might make and we have an additional $10 million U.S. line which could be used to service those acquisitions. Okay. So you're a biomed company. Let's talk a little bit about your product line because you just added to your product line as well. So your base product line, how many products now do you have on offer? So we currently sell 12 products and six of which are actively marketed by the company and it's split within three different business units. Respiratory where we have three products, two in asthma and one in allergy. The ophthalmic unit which is relatively new. It came as a result of this acquisition where we have a product for dry eye and for glaucoma or high blood pressure in the eye. And the third unit actually has more products. It's more of our hospital slash specialty division which is being led by a product called Redesco which is currently I believe our number two selling product and with upsides. So diversified portfolio. Each business unit has its own business unit head, its own commercial team. So the sales reps are dedicated to those products. These reps are all our own employees and once we complete the ophthalmic business unit by the end of October we'll have about 125 employees. So and you just recently added two new products to your product line. Tell us a little bit about those. We added actually three new products. We acquired licenses from the VARDIS for two ophthalmic products at the end of July so they did not impact our July revenue numbers but start as of October 1st. These currently these two products in our ophthalmic unit is actually our number one revenue driving division right now. One is for dry eye. One is for glaucoma and as I mentioned they historically did 23 million in the prior 12 months and we expect to be able to build that over the course of the next four years to probably double that number. So 40 to 45 million. The other product that fits well with our respiratory unit that we also acquired on July 29th is a allergy drug used for severe allergic reactions called Allergek. It currently does four million dollars of revenue in Canada. We expect to be able to grow that. It has only one other competitor in a 90 million dollar market. This product has clear advantages in terms of its ease of use. It actually it's an auto injector. The device actually speaks to you and I'll give you just an example of this is the size of the device easily carryable for those people at Needlephobic. You don't see the needle and it's used in situations where you have an intense allergic reaction. So very three new products. Current additional revenues 27 million but we expect to be able to build these three products to revenues in the high 60s to low 70s over the course of the next few years. So significant revenue jump for us immediately and also in the longer term. That's great and so and these are all products obviously then they're Health Canada approved. They're out there. They're actually being used by people available for prescription and use in hospitals. That's right. I mean if you look at our Zidra product which is a prescription dry eye medication and dry eye has a long way to go in Canada. It's not well diagnosed. There's certainly a lot of people that are suffering from dry eye that are not seeking medications. Our job is to increase awareness there but in the US Zidra does almost 500 million dollars of revenue for Novartis. So this is a big product in the US. It's advertised on TV in the US. In the Canadian market the product has not been promoted for over a year and we expect that the promotion will help drive up revenues for this product. We believe in terms of dry eye one of the best products on the market. Well that leads me to my last question. Everyone wants to know the future especially with a listed company. What's coming next? What are your revenue expectations and when will we see them hit the balance sheet and be reported? Well our current revenue run rate with these three new products that we've just acquired is in the high 40s to low 50 million dollar range. So it puts us certainly as a solid mid-tier Canadian player. For 2023 we haven't provided any guidance but I would expect that our numbers should be higher than that 50 million. And if I look at all our products, if everything went very well with all of them in terms of reaching their peak potential through great execution over the course of the next four to five years, we have products currently which have the potential to drive us to revenue base of well over 200 million dollars. And that's our existing product portfolio. So again six products being promoted out of 12. Most of our team will have shortly about 80 or 85 commercial people that's out in the field talking to physicians, talking to pharmacists, talking to other health care providers. And it's really execution. It's being able to deliver the message. We know the products are effective especially our enters there which has great clinical results and great results with the first patients that have been on it. We have over 700 doctors that currently prescribe enters there and our objective is to grow that significantly. So we're hitting on all our cylinders. Time is just a question of time. It's a question of getting out there and getting the information out to physicians about the benefits of our drugs. Steve, all very exciting. Look forward to having you back and giving us an update to see all these cylinders hitting. We're looking forward to being back and giving your audience more information about the progress that we're making. Thank you, Steve. Look forward to it. Great. Thanks, Steve.